Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Equity Average (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Equity Average for 4 consecutive years, with $446.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 15.7% to $446.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $446.0 million, a 15.7% decrease, with the full-year FY2025 number at $472.0 million, up 11.14% from a year prior.
  • Equity Average was $446.0 million for Q4 2025 at Day One Biopharmaceuticals, down from $455.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $529.1 million in Q4 2024 to a low of $301.8 million in Q2 2024.
  • A 4-year average of $396.8 million and a median of $376.9 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: fell 16.92% in 2024, then soared 55.81% in 2025.
  • Day One Biopharmaceuticals' Equity Average stood at $347.6 million in 2022, then grew by 5.91% to $368.1 million in 2023, then surged by 43.75% to $529.1 million in 2024, then dropped by 15.7% to $446.0 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Equity Average are $446.0 million (Q4 2025), $455.9 million (Q3 2025), and $470.2 million (Q2 2025).